Table 4. Initial sites of recurrence after pulmonary resections by oncogenic status.
| Recurrent site | Total | EGFR | KRAS | ALK | TN | P value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N=281 | % | N=135 | % | N=33 | % | N=13 | % | N=100 | % | ||||||
| Locoregional site | 83 | 29.5 | 38 | 28.1 | 6 | 18.2 | 5 | 38.5 | 34 | 34.0 | 0.31 | ||||
| Lung | 88 | 31.3 | 43 | 31.9 | 14 | 42.4 | 4 | 30.8 | 27 | 27.0 | 0.64 | ||||
| Pleura | 45 | 16.0 | 30 | 22.2 | 1 | 3.0 | 2 | 15.4 | 12 | 12.0 | 0.043 | ||||
| Brain | 52 | 18.5 | 25 | 18.5 | 8 | 24.2 | 2 | 15.4 | 17 | 17.0 | 0.79 | ||||
| Bone | 65 | 23.1 | 31 | 23.0 | 10 | 30.3 | 4 | 30.8 | 20 | 20.0 | 0.65 | ||||
| Adrenal gland | 12 | 4.3 | 0 | 0.0 | 1 | 3.0 | 0 | 0.0 | 11 | 11.0 | 0.001 | ||||
| Single organ | 167 | 59.4 | 81 | 60.0 | 19 | 57.6 | 8 | 61.5 | 59 | 59.0 | 0.99 | ||||
EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KRAS, Kirsten rat sarcoma viral oncogene homolog; TN, triple negative.